<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34718893</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>28</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1434-9949</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>41</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Clinical rheumatology</Title>
          <ISOAbbreviation>Clin Rheumatol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Progranulin correlated with rapid progressive interstitial lung disease in dermatomyositis with anti-melanoma differentiation-associated gene 5 antibody.</ArticleTitle>
        <Pagination>
          <StartPage>757</StartPage>
          <EndPage>763</EndPage>
          <MedlinePgn>757-763</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10067-021-05816-2</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">This study aimed to detect the expression of progranulin (PGRN) and elucidate associations with clinical features in dermatomyositis (DM) patients with anti-melanoma differentiation-associated gene 5 (anti-MDA5) antibody.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">We enrolled 40 DM patients with anti-MDA5 antibody, 20 patients with antisynthetase syndrome (ASS; disease control), and 20 healthy individuals (healthy control, HC). The clinical features of patients with anti-MDA5 antibody and anti-histidyl-tRNA antibody were collected. The level of PGRN in the serum was tested by ELISA.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">The PGRN levels in DM patients with anti-MDA5 antibody (166.74 ± 97.95 ng/ml) were significantly higher than those in patients with ASS (82.66 ± 40.50 ng/ml; p &lt; 0.001) and in HC (42.34 ± 18.69 ng/ml; p &lt; 0.001). Patients with rapid progressive interstitial lung disease (RP-ILD) in DM with anti-MDA5 antibody (213.57 ± 114.05 ng/ml) had higher levels of PGRN than those without RP-ILD (135.51 ± 72.41 ng/ml; p = 0.012). ROC analysis showed an AUC value at 0.715 (95% CI, 0.541-0.888) for diagnosis of RP-ILD in DM patients with anti-MDA5 antibody. The expression of PGRN was positively correlated with the levels of ALT, AST, CK, LDH and ferritin (all p &lt; 0.05).</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our results indicated PGRN had great potential as a valuable serum marker of RP-ILD in DM with anti-MDA5 antibody. Key Points The level of PGRN was elevated in DM patients with anti-MDA5 antibody, especially for those with RP-ILD.</AbstractText>
          <CopyrightInformation>© 2021. International League of Associations for Rheumatology (ILAR).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Shanshan</LastName>
            <ForeName>Li</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Rheumatology, China-Japan Friendship Hospital, No.2 Yinghua East st, Chaoyang District, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yamei</LastName>
            <ForeName>Zhang</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Rheumatology, China-Japan Friendship Hospital, No.2 Yinghua East st, Chaoyang District, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ling</LastName>
            <ForeName>Zhang</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, China-Japan Friendship Hospital, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xin</LastName>
            <ForeName>Lu</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Rheumatology, China-Japan Friendship Hospital, No.2 Yinghua East st, Chaoyang District, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guochun</LastName>
            <ForeName>Wang</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Rheumatology, China-Japan Friendship Hospital, No.2 Yinghua East st, Chaoyang District, Beijing, China. guochunwang@hotmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>31</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Clin Rheumatol</MedlineTA>
        <NlmUniqueID>8211469</NlmUniqueID>
        <ISSNLinking>0770-3198</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C492314">GRN protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000077153">Progranulins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.6.1.-</RegistryNumber>
          <NameOfSubstance UI="C452815">IFIH1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.6.4.13</RegistryNumber>
          <NameOfSubstance UI="D000072640">Interferon-Induced Helicase, IFIH1</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003882" MajorTopicYN="Y">Dermatomyositis</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000072640" MajorTopicYN="N">Interferon-Induced Helicase, IFIH1</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017563" MajorTopicYN="Y">Lung Diseases, Interstitial</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077153" MajorTopicYN="N">Progranulins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Dermatomyositis</Keyword>
        <Keyword MajorTopicYN="N">Melanoma differentiation-associated gene 5</Keyword>
        <Keyword MajorTopicYN="N">Progranulin</Keyword>
        <Keyword MajorTopicYN="N">Rapidly progressive interstitial lung disease</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>31</Day>
          <Hour>21</Hour>
          <Minute>21</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34718893</ArticleId>
        <ArticleId IdType="doi">10.1007/s10067-021-05816-2</ArticleId>
        <ArticleId IdType="pii">10.1007/s10067-021-05816-2</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>DeWane ME, Waldman R, Lu J (2020) Dermatomyositis: clinical features and pathogenesis. J Am Acad Dermatol 82:267–281</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaad.2019.06.1309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kurtzman DJB, Vleugels RA (2018) Anti-melanoma differentiation-associated gene 5 (MDA5) dermatomyositis: a concise review with an emphasis on distinctive clinical features. J Am Acad Dermatol 78:776–785</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaad.2017.12.010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li L, Wang Q, Yang F, Wu C, Chen S, Wen X et al (2017) Anti-MDA5 antibody as a potential diagnostic and prognostic biomarker in patients with dermatomyositis. Oncotarget 8:26552–26564</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.15716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang K, Vinik O, Shojania K, Yeung J, Shupak R, Nimmo M et al (2019) Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review. Rheumatol Int 39:1971–1981</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00296-019-04398-2</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jian J, Konopka J, Liu C (2013) Insights into the role of progranulin in immunity, infection, and inflammation. J Leukoc Biol 93:199–208</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1189/jlb.0812429</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bateman A, Cheung ST, Bennett HPJ (2018) A brief overview of progranulin in health and disease. Methods Mol Biol 1806:3–15</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-4939-8559-3_1</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jian J, Li G, Hettinghouse A, Liu C (2018) Progranulin: a key player in autoimmune diseases. Cytokine 101:48–55</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cyto.2016.08.007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei J, Hettinghouse A, Liu C (2016) The role of progranulin in arthritis. Ann N Y Acad Sci 1383:5–20</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/nyas.13191</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jing C, Zhang X, Song Z, Zheng Y, Yin Y (2020) Progranulin mediates proinflammatory responses in systemic lupus erythematosus: implications for the pathogenesis of systemic lupus erythematosus. J Interferon Cytokine Res 40:33–42</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/jir.2019.0047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanaka A, Tsukamoto H, Mitoma H, Kiyohara C, Ueda N, Ayano M et al (2015) Serum progranulin levels are elevated in dermatomyositis patients with acute interstitial lung disease, predicting prognosis. Arthritis Res Ther 17:27</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13075-015-0547-z</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR et al (2004) 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden. The Netherlands Neuromuscul Disord 14:337–345</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nmd.2004.02.006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Solomon J, Swigris JJ, Brown KK (2011) Myositis-related interstitial lung disease and antisynthetase syndrome. J Bras Pneumol 37:100–109</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1590/S1806-37132011000100015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen J, Li S, Shi J, Zhang L, Li J, Chen S et al (2016) Serum progranulin irrelated with Breg cell levels, but elevated in RA patients, reflecting high disease activity. Rheumatol Int 36:359–364</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00296-015-3372-4</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qiu F, Song L, Ding F, Liu H, Shu Q, Yang N et al (2013) Expression level of the growth factor progranulin is related with development of systemic lupus erythematosus. Diagn Pathol 8:88</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1746-1596-8-88</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang W, Lu Y, Tian QY, Zhang Y, Guo FJ, Liu GY et al (2011) The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science 332:478–484</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1199214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson J, Yeter K, Rajbhandary R, Neal R, Tian Q, Jian J et al (2017) Serum progranulin levels in Hispanic rheumatoid arthritis patients treated with TNF antagonists: a prospective, observational study. Clin Rheumatol 36:507–516</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10067-016-3467-7</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park B, Buti L, Lee S, Matsuwaki T, Spooner E, Brinkmann MM et al (2011) Granulin is a soluble cofactor for toll-like receptor 9 signaling. Immunity 34:505–513</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2011.01.018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanaka A, Tsukamoto H, Mitoma H, Kiyohara C, Ueda N, Ayano M et al (2012) Serum progranulin levels are elevated in patients with systemic lupus erythematosus, reflecting disease activity. Arthritis Res Ther 14:R244</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/ar4087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abella V, Pino J, Scotece M, Conde J, Lago F, Gonzalez-Gay MA et al (2017) Progranulin as a biomarker and potential therapeutic agent. Drug Discov Today 22:1557–1564</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.drudis.2017.06.006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Horiike Y, Suzuki Y, Fujisawa T, Yasui H, Karayama M, Hozumi H et al (2019) Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD. Rheumatology (Oxford) 58:2143–2152</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/kez185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Enomoto Y, Suzuki Y, Hozumi H, Mori K, Kono M, Karayama M et al (2017) Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease. Arthritis Res Ther 19:9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13075-016-1214-8</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giemza-Stokłosa J, Islam MA, Kotyla PJ (2019) Hyperferritinaemia: an iron sword of autoimmunity. Curr Pharm Des 25:2909–2918</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1381612825666190709202804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kernan KF, Carcillo JA (2017) Hyperferritinemia and inflammation. Int Immunol 29:401–409</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/intimm/dxx031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishioka A, Tsunoda S, Abe T, Yoshikawa T, Takata M, Kitano M et al (2019) Serum neopterin as well as ferritin, soluble interleukin-2 receptor, KL-6 and anti-MDA5 antibody titer provide markers of the response to therapy in patients with interstitial lung disease complicating anti-MDA5 antibody-positive dermatomyositis. Mod Rheumatol 29:814–820</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14397595.2018.1548918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Motegi SI, Sekiguchi A, Toki S, Kishi C, Endo Y, Yasuda M et al (2019) Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease. Eur J Dermatol 29:511–517</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1684/ejd.2019.3634</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ishikawa N, Hattori N, Yokoyama A, Kohno N (2012) Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases. Respir Investig 50:3–13</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.resinv.2012.02.001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonella F, Costabel U (2014) Biomarkers in connective tissue disease-associated interstitial lung disease. Semin Respir Crit Care Med 35:181–200</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-0034-1371527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanaoka M, Katsumata Y, Kawasumi H, Kawaguchi Y, Yamanaka H (2019) KL-6 is a long-term disease-activity biomarker for interstitial lung disease associated with polymyositis/dermatomyositis, but is not a short-term disease-activity biomarker. Mod Rheumatol 29:625–632</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14397595.2018.1553488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu Y, Xu X, Liu L, Mao S, Feng T, Lu Y et al (2016) Progranulin deficiency leads to severe inflammation, lung injury and cell death in a mouse model of endotoxic shock. J Cell Mol Med 20:506–517</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jcmm.12756</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kishaba T, McGill R, Nei Y, Ibuki S, Momose M, Nishiyama K et al (2018) Clinical characteristics of dermatomyosits/polymyositis associated interstitial lung disease according to the autoantibody. J Med Invest 65(3.4):251–257</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2152/jmi.65.251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okabayashi H, Ichiyasu H, Hirooka S, Akaike K, Kojima K, Jodai T et al (2017) Clinical effects of direct hemoperfusion using a polymyxin B-immobilized fiber column in clinically amyopathic dermatomyositis-associated rapidly progressive interstitial pneumonias. BMC Pulm Med 17(1):134</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12890-017-0479-2</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
